R&D | Cutting-edge science and innovative research

News

Andy Plump to step down as Takeda's R&D chief

Andy Plump, credited with a 'soup-to-nuts' overhaul of Takeda's R&D in more than a decade of leadership at the division, has announced his retirement.

News

Bottle of Qulipta superimposed on image of woman holding head against sun dappled wall

AbbVie charts a new course for CGRPs in menstrual migraine

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.

News

Encoded raises $275m for Dravet therapy and other financings

Our round-up of biotech financings is headed by Encoded, which has raised $275m to advance its gene therapy for Dravet syndrome into pivotal trials.

News

Could UK clinical trial revamp unlock closer ties with Canad...

Two senior figures in Canada's life science sector have said they see scope for greater collaboration with the UK following clinical trial reforms.

R&D

Mosquitoes, malaria, and UK R&D viral disease vaccine invest...

The UK must sustain investment in malaria R&D as it faces a “perfect storm” of challenges, including mosquito resistance to existing tools.

News

Lilly takes on Vertex in non-opioid pain with SiteOne buy

Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.

News

ASCO 25: Merus bispecific scores again in HNSCC

For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye.

R&D

Recent breakthroughs in 3D bioprinting: A look at trends and...

3D bioprinting technology is bringing a new revolutionary wave to the healthcare industry.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Andy Plump to step down as Takeda's R&D chief

Andy Plump, credited with a 'soup-to-nuts' overhaul of Takeda's R&D in more than a decade of leadership at the division, has announced his retirement.

News

AbbVie charts a new course for CGRPs in menstrual migraine

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Press Releases

Partner Content

Navigating Change: Key Industry Insights at PHARMAP 2026

PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor

Views & Analysis

R&D

Mosquitoes, malaria, and UK R&D viral disease vaccine invest...

The UK must sustain investment in malaria R&D as it faces a “perfect storm” of challenges, including mosquito resistance to existing tools.

R&D

Digital pill, molecules inside, and digital hand with precision laser

Scientists and algorithms: Finding the right balance in mode...

The future of drug development is not scientists versus algorithms. It is scientists and algorithms working together.

R&D

Back to basics: X-ray inspection in pharmaceutical and medic...

In pharma manufacturing, x-ray inspection supports a range of quality control processes.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

R&D

CAMP4 on a new class of ASO in gene under expression

CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study

Video

R&D

two healthcare professionals looking at chart

Sponsored

Decentralisation by design: Bringing the trial closer withou...

In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.

R&D

Sponsored

Patient population first: the strategy behind country decisi...

R&D

Sponsored

IQVIA on reducing complexity and workload for clinical trial...

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.